MST3 Modulator Oligonucleotide Lipid Accumulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies fail to identify compounds that modulate the expression or activity of MST3, a kinase involved in lipid metabolism, which is relevant for various human diseases such as obesity, type 2 diabetes, and fatty liver diseases.
Innovation Solution
A method involving the administration of oligonucleotides or polynucleotides that are hybridizable to the nucleic acid sequence of MST3, thereby suppressing intracellular accumulation of cholesteryl ester and treating metabolic diseases like NAFLD, NASH, fatty pancreas disease, and fatty kidney disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current technologies are used to identify compounds modulating MST3, then existing therapeutic approaches can be maintained, but compounds that modulate MST3 expression or activity cannot be identified
Solution Approach 1:
The patent introduces an intermediary screening system using cell lines with modified MST3 expression levels (overexpressing or depleted) as mediators to identify compounds that modulate MST3. This intermediary system enables the detection of MST3 modulators that would otherwise be undetectable by current technologies, resolving the contradiction between maintaining existing approaches and identifying new modulators.
2Object-affected harmful factors
If compounds modulating MST3 are identified and used, then lipid accumulation in metabolic diseases can be suppressed, but the complexity of the treatment approach increases
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism of MST3 in lipid metabolism by using oligonucleotides that specifically bind to and modulate MST3 expression or activity. This extracted targeted approach suppresses lipid accumulation through β-oxidation and TAG secretion while reducing free fatty acid uptake, providing a precise treatment that addresses the harmful effect without requiring complex multi-target interventions.
3Quantity of substance
If oligonucleotides are used to suppress MST3 expression, then intracellular cholesteryl ester accumulation is reduced, but the specificity of the treatment must be ensured to avoid off-target effects
Solution Approach 1:
The patent applies local quality by designing oligonucleotides with specific sequences that bind to particular regions of the MST3 gene or mRNA (such as promoter regions, coding sequences, or specific exons). This localized binding ensures that the oligonucleotides specifically modulate MST3 expression without affecting other genes or pathways, thereby reducing cholesteryl ester accumulation with high specificity and avoiding off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively suppresses lipid accumulation in human hepatocytes by increasing β-oxidation and TAG secretion, while reducing free fatty acid uptake and lipid synthesis, thus providing a potential treatment for metabolic diseases.
Implementation Method 1
The oligonucleotide or polynucleotide is hybridizable to the nucleic acid sequence of SEQ ID NO:1, or a nucleic acid sequence complementary to SEQ ID NO:1
Data Source
AI summary
The present invention relates to methods for identifying compounds that can have an effect on lipid metabolism, and thereby have a high relevance for several human diseases including but not restricted to obesity, type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), fatty pancreas disease, and fatty kidney disease. More specifically, the present invention relates to methods for identifying modulators of the expression or the activity of the human kinase Mammalian Sterile20-like 3 (MST3) and use of such modulators in the treatment of metabolic disease.